InMed Pharmaceuticals Inc. (INM) Appoints Nicole Lemerond to its Board

InMed Pharmaceuticals Inc. (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately.

Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public and private company management teams and boards to increase stakeholder value. She established and led healthcare groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Ms. Lemerond holds a Bachelor of Science degree from Cornell University and is a CFA charterholder.

Contemporaneous with Ms. Lemerond’s appointment, Adam Cutler has decided to transition off the Board of Directors. Mr. Cutler has served on the Board since 2015, during which time his financial and healthcare expertise has been instrumental in advancing the strategic initiatives of the Company. Over the years, Mr. Cutler has served as Chair of the Audit Committee as well as a member Governance and Nomination Committee. Ms. Lemerond will replace Mr. Cutler as a member of the Audit Committee and as a member of the Governance and Nomination Committee.

William Garner, MD, InMed’s Chairman of the Board of Directors, commented: “I am delighted to welcome Ms. Lemerond to the Board of Directors at InMed. Nicole joins us with tremendous financial and healthcare experience and will prove to be an invaluable asset to the Company. Additionally, on behalf of the Company, I would like to extend our sincere appreciation to Mr. Cutler for his significant contributions over the last 6+ years. His dedication and extensive expertise have been crucial in the strategic development of InMed and we wish him the best with his future endeavors.”

You May Also Be Interested In

• Evercore says mutual funds cut bank stock holdings in second quarter
• Merit Medical names new EVP of global operations as COO prepares to exit
• Kite Realty Group names new VP of capital markets and IR